Human Growth Hormone Market by Application (Growth Hormone Deficiency, Chronic Kidney Disease, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome and Other Applications), By Route of Administration (Subcutaneous, Intramuscular and Intravenous), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Human Growth Hormone Market size is expected to be worth around US$ 19.8 Billion by 2034, from US$ 5.9 Billion in 2024, growing at a CAGR of 12.7% during the forecast period from 2025 to 2034. North America held a dominant market position, capturing more than a 39.2% share and holds US$ 2.4 Billion market value for the year.

The global Human Growth Hormone (HGH) market is witnessing significant growth, fueled by advancements in biotechnology, increasing awareness of growth-related disorders, and the rising adoption of growth hormone therapies. Human growth hormone, or somatotropin, plays a vital role in promoting growth and development and is extensively utilized to address conditions such as growth hormone deficiency (GHD), Turner syndrome, Prader-Willi syndrome, chronic kidney diseases, and other related disorders. The market is further bolstered by the expanding use of hGH in non-growth-related areas, including muscle-wasting diseases and aging-related hormonal therapies.

• According to NIH, the prevalence of Turner syndrome among all pregnancy outcomes is 3.2 cases per 10,000 live female births.
• Turner syndrome occurs in approximately 1 in 2,000 to 1 in 2,500 individuals assigned female at birth.
• As per NIH, the estimated prevalence of Prader-Willi syndrome (PWS) ranges from 1 in 10,000 to 1 in 30,000 across various populations.

Key growth drivers include the growing incidence of growth disorders, increased emphasis on pediatric care, and continuous innovations in recombinant DNA technology. Emerging solutions, such as long-acting growth hormone formulations and needle-free delivery systems, are enhancing patient compliance and broadening treatment adoption.

Additionally, the off-label use of hGH for anti-aging and athletic performance is contributing to market growth, though it poses regulatory challenges. Challenges such as high treatment costs, stringent regulatory frameworks, and potential risks associated with long-term hormone use could hinder market progress.

Leading players, including Pfizer, Novo Nordisk, Eli Lilly, and Sandoz, are focusing on strategic collaborations, R&D investments, and geographical expansion to strengthen their market presence. The global human growth hormone market is positioned for sustained growth, underpinned by technological advancements and the expansion of therapeutic applications.

Global Human Growth Hormone Market, Global Analysis, 2020-2024 (US$ Billion)

Key Takeaways

• The Human Growth Hormone market generated a revenue of US$ 5.9 Billion and is predicted to reach US$ 19.8 Billion, with a CAGR of 12.7%.
• Based on the Application, the Growth Hormone Deficiency segment generated the most revenue for the market with a market share of 46.4%.
• Based on the Route of Administration, the subcutaneous segment generated the most revenue for the market with a market share of 82.0%.
• Based on the Distribution Channel, the Hospital Pharmacy segment generated the most revenue for the market with a market share of 45.1%.
• Region-wise, North America remained the lead contributor to the market, by claiming the highest market share, amounting to 40.4%.

Application Analysis

Growth Hormone Deficiency (GHD) continues to dominate the application segment of the global human growth hormone (HGH) market, accounting for a significant share of 46.4% in 2024. This segment’s prominence is largely driven by the increasing incidence of GHD in both children and adults. In children, GHD is typically caused by congenital conditions, pituitary tumors, or trauma, leading to impaired growth and development. In adults, GHD can result from pituitary gland dysfunction, which affects metabolic processes, muscle mass, and overall health.

The growing awareness of the condition and the effectiveness of HGH therapy in treating GHD has contributed to the segment’s dominance. HGH treatment plays a crucial role in promoting growth in children with stunted development and improving metabolic functions, body composition, and overall quality of life in adults.

The rise in the diagnosis and treatment of GHD, combined with advancements in recombinant HGH products, has further fueled market growth. With increasing healthcare access, especially in emerging regions, more patients are seeking HGH therapy, driving this segment’s continued market leadership. Additionally, the approval of rHGH products for pediatric and adult GHD has further strengthened the growth hormone deficiency segment’s dominance, solidifying its substantial contribution to the overall HGH market.

Global Human Growth Hormone Market, by Application, 2020-2024 (US$ Billion)

Route of Administration Analysis

The subcutaneous route of administration dominated the route of administration segment in the global human growth hormone (HGH) market, capturing an impressive 82.0% market share in 2024. This dominance is primarily attributed to the ease of administration, patient convenience, and the proven effectiveness of subcutaneous injections for delivering HGH therapy.

Subcutaneous injections involve injecting the hormone just under the skin, which allows for gradual absorption into the bloodstream. This method is preferred for long-term treatments, as it is less invasive than intravenous administration and can be easily performed by patients themselves at home, reducing the need for frequent hospital visits.

Additionally, the availability of pre-filled syringes and devices such as pens has further contributed to the popularity of subcutaneous administration, providing patients with a more user-friendly experience. These factors, coupled with the high efficacy of subcutaneous HGH delivery for conditions such as growth hormone deficiency (GHD) and muscle-wasting diseases, have cemented its position as the leading route of administration in the HGH market. The continued development of advanced drug delivery devices is expected to further enhance the growth of this segment in the coming years.

Global Human Growth Hormone Market, by Route of Administration, 2020-2024 (US$ Billion)

Distribution Channel Analysis

The hospital pharmacy segment dominates the distribution channel in the global human growth hormone (HGH) market, accounting for a significant share. This dominance is driven by the critical role hospitals play in diagnosing and treating growth hormone deficiencies and other conditions requiring HGH therapy. Hospital pharmacies are well-equipped to manage specialized medications, ensuring the safe storage and distribution of HGH products.

Additionally, healthcare providers in hospitals closely monitor patients receiving HGH therapy, ensuring appropriate dosages and minimizing risks. The reliable distribution network and trusted medical oversight provided by hospital pharmacies make them the preferred channel for HGH treatment.

Global Human Growth Hormone Market, by Distribution Channel, 2020-2024 (US$ Billion)

Key Market Segments

By Application

• Growth Hormone Deficiency
• Chronic Kidney Disease
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Other Applications

By Route of Administration

• Subcutaneous
• Intramuscular
• Intravenous

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Drivers

Rising Prevalence of Growth Hormone Deficiency and Other Related Disorders

The global prevalence of growth hormone deficiency (GHD) in both children and adults is a significant driver of the human growth hormone (HGH) market. Isolated GHD incidence has been reported at approximately 1 case per 1,800 children in Sri Lanka. In India, the prevalence of GHD among children with short stature varies significantly, ranging from 2.8% to 69%, with a higher likelihood of occurrence post-neurosurgical interventions.

The rising demand for human growth hormone (HGH) can be attributed to the increasing prevalence of various medical conditions that require growth hormone therapy. Conditions such as Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency often necessitate HGH treatment. For instance, Turner syndrome affects approximately 1 in 2,000 to 1 in 2,500 females, though milder cases may remain undiagnosed or only be detected later in life. In China alone, an estimated 8 million children under the age of 18 were reported to have short stature in 2022, highlighting the need for growth-related treatments.

Additionally, the global obesity epidemic has further expanded the potential patient base for HGH therapy, as obesity is a recognized risk factor for growth hormone deficiency (GHD). Data from the World Health Organization (WHO) indicate that more than 1 billion individuals worldwide are classified as obese, including 650 million adults, 340 million adolescents, and 39 million children. This growing prevalence underscores the increasing significance of HGH therapies, not only for managing GHD but also for addressing related health complications.

Restrains

Side Effects and Safety Concerns

The potential side effects and long-term safety concerns associated with human growth hormone (HGH) treatment present significant challenges to market growth. In the pediatric segment, where HGH is widely prescribed for growth deficiencies, side effects such as joint and muscle pain, increased insulin resistance, and progression of scoliosis have been reported. Among adults, particularly those using HGH for off-label purposes like anti-aging or bodybuilding, common adverse effects include edema, carpal tunnel syndrome, arthritis, and an elevated risk of diabetes due to the hormone’s impact on glucose metabolism.

Published studies underscore these concerns. For instance, research in the journal Endocrine indicates that HGH therapy may lead to edema in 5-18% of patients, along with arthralgia and carpal tunnel syndrome. Long-term risks, including increased cancer susceptibility and adverse cardiovascular outcomes, further constrain the market. The hormone’s influence on lipid metabolism, causing elevated LDL cholesterol and reduced HDL cholesterol, has been linked to heightened risks of cardiovascular disease.

Moreover, findings from the Journal of Clinical Endocrinology & Metabolism highlight additional risks such as insulin resistance and dyslipidemia associated with prolonged HGH use. These safety concerns have led regulatory authorities, including the FDA and EMA, to enforce stringent prescribing guidelines, creating a regulatory barrier that limits the market’s growth potential.

Opportunities

Increasing Applications beyond Hormone Growth Deficiency

The global human growth hormone (HGH) market is expanding beyond traditional indications, driven by an evolving understanding of the hormone’s diverse physiological roles. Initially used to treat growth hormone deficiencies in children and adults, HGH is now being explored for its potential in managing a broader range of conditions, creating new opportunities for market growth.

HGH has demonstrated significant promise in addressing muscle-wasting diseases, such as HIV/AIDS-related wasting and cancer-associated cachexia. Its ability to stimulate muscle growth and facilitate weight gain is instrumental in improving the quality of life for patients. Research highlights that six months of HGH treatment can result in substantial weight gain in patients with HIV-associated wasting, showcasing its therapeutic value.

Emerging studies are also investigating the effects of HGH and insulin-like growth factor-1 (IGF-1) on brain function, indicating potential cognitive and neurological benefits. Additionally, HGH’s regenerative properties are gaining attention for their potential to accelerate recovery from musculoskeletal injuries. While regulatory concerns and restrictions related to performance enhancement currently limit its widespread use for injury recovery, ongoing research may pave the way for new medical protocols.

Notably, researchers at the University of Illinois at Chicago found that HGH activates the Foxm1 gene, which plays a critical role in tissue recovery and cell division, further underscoring its potential in regenerative medicine.

Impact of Macroeconomic / Geopolitical Factors

The global human growth hormone (HGH) market is significantly influenced by macroeconomic and geopolitical factors. Economic instability and inflationary pressures can impact healthcare budgets and consumer affordability, particularly in emerging markets, thereby limiting access to HGH treatments. Conversely, rising healthcare expenditure in developed nations supports market growth through increased adoption of advanced therapies.

Geopolitical factors, such as trade restrictions, regulatory disparities, and international sanctions, can disrupt the global supply chain for HGH, affecting the availability of raw materials and finished products. Moreover, geopolitical tensions may shift focus and resources away from healthcare advancements, delaying regulatory approvals and market expansion.

Additionally, evolving healthcare policies and reimbursement frameworks in key regions play a pivotal role. Favorable policies can enhance accessibility, while stringent regulations, particularly concerning safety and ethical use, may restrain market growth. The global obesity epidemic and aging population, intertwined with broader socioeconomic trends, further amplify the market’s sensitivity to these factors.

Trends

The global human growth hormone (HGH) market is witnessing several key trends shaping its growth. One major trend is the increasing focus on biosimilar development, driven by patent expirations of branded HGH products. Biosimilars offer cost-effective alternatives, enhancing accessibility and expanding the market, particularly in price-sensitive regions.

Technological advancements are also revolutionizing HGH delivery methods. Innovations such as needle-free devices, auto-injectors, and long-acting HGH formulations are improving patient convenience, adherence, and outcomes. Additionally, research into recombinant DNA technology continues to drive the development of safer and more effective HGH therapies.

The growing adoption of HGH in non-traditional applications, including muscle-wasting diseases, regenerative medicine, and injury recovery, highlights its expanding therapeutic potential. Furthermore, increased awareness about growth disorders and supportive government initiatives in healthcare are fueling market demand. Finally, the rising prevalence of conditions such as Turner syndrome and Prader-Willi syndrome continues to bolster growth in this sector.

Regional Analysis

North America Dominates the Global Human Growth Hormone Market

North America held a dominant position in the global human growth hormone (HGH) market with the share of 40.4% in 2024, driven by robust healthcare infrastructure, high awareness of growth disorders, and significant investments in research and development. The region benefits from the strong presence of key market players, advanced biopharmaceutical manufacturing capabilities, and early adoption of innovative therapies, such as long-acting HGH formulations and needle-free delivery systems.

Supportive government initiatives and reimbursement policies further enhance access to HGH treatments in the region. The prevalence of growth hormone deficiencies and associated conditions, such as Turner syndrome, Prader-Willi syndrome, and muscle-wasting diseases, is a key factor driving demand. Additionally, increasing off-label usage for anti-aging and performance enhancement contributes to market growth, despite regulatory constraints.

The U.S., in particular, dominates due to its high healthcare expenditure, extensive clinical research, and favorable regulatory environment, making North America a significant revenue-generating region in the HGH market.

Global Human Growth Hormone Market, by Region, 2020-2024 (US$ Billion)

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The global human growth hormone (HGH) market is highly competitive, characterized by the presence of established players and emerging biosimilar manufacturers. Key players such as Pfizer, Novo Nordisk, Merck KGaA, and Eli Lilly dominate the market with a strong portfolio of recombinant HGH products and long-acting formulations. The rising adoption of biosimilars is intensifying competition, particularly in price-sensitive regions.

Companies are focusing on strategic collaborations, R&D investments, and technological advancements in delivery systems to maintain a competitive edge. Additionally, market players are expanding their geographic presence and targeting new therapeutic applications to capitalize on the growing demand for HGH therapies.

Top Key Players in the Human Growth Hormone Market

• Ferring Pharmaceuticals
• Pfizer Inc.
• Ascendis Pharma
• Eli Lilly and Company
• Novo Nordisk AS
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• AnkeBio Co. Ltd
• Genetech Inc.
• Sandoz UK

Recent Developments

• In September 2023, Ascendis Pharma A/S introduced SKYTROFA® (lonapegsomatropin) in Germany. This marked the launch of the growth hormone product, which has received approval within the European Union for the treatment of children and adolescents aged 3 to 18 years. It is intended for those who experience growth failure resulting from inadequate natural growth hormone secretion, a condition known as growth hormone deficiency (GHD).
• In January 2022, Pfizer Inc. and OPKO Health, Inc. made an announcement regarding the response from the U.S. Food and Drug Administration concerning the Biologics License Application (BLA) for somatrogon. Somatrogon is a long-acting recombinant human growth hormone under investigation for its potential use in the cure of growth hormone deficiency (GHD) in pediatric patients. Pfizer currently reviewing the feedback provided by the FDA and intends to collaborate with the organization to chart a suitable course of action.

Report Scope